%0 Journal Article %A VERONICA LUENGAS-WUERZINGER %A FRIEDERIKE RAWERT %A SABRINA CLAßEN-VON SPEE %A SAHER BARANSI %A ESTHER SCHULER %A KATHARINA CARRIZO %A PETER MALLMANN %A BJOERN LAMPE %T Role of the Cardiophrenic Lymph Node Status After Neoadjuvant Chemotherapy in Primary Advanced Ovarian Cancer %D 2021 %R 10.21873/anticanres.15317 %J Anticancer Research %P 5025-5031 %V 41 %N 10 %X Background/Aim: This study investigated the cardiophrenic lymph node (CPLN) status before and after neoadjuvant chemotherapy (NACT), as its presence seems to have a rather prognostic significance in patients with advanced ovarian cancer. Patients and Methods: The baseline computed tomography scans of 66 patients with advanced ovarian cancer primary treated with NACT between March 2015 and June 2020 were reviewed. A CPLN enlargement was defined as ≥5 mm. Results: 44% (n=29) of the patients had enlarged CPLNs; 10.7% (n=3) showed a complete response, 71.4% (n=20) a partial response, and 17.9% (n=5) a stable disease after NACT. There was no significant difference between the response to NACT measured according to the status of CPLN compared to other biomarkers in the CPLN group. Conclusion: Patients with CPLN enlargement have a tendency to an impaired prognosis. The response of CPLN to NACT was comparable to the response of established biomarkers, adding a monitoring function to the CPLN. %U https://ar.iiarjournals.org/content/anticanres/41/10/5025.full.pdf